PACS vendors shouldn't oversell the technology

Article

PACS vendors shouldn't oversell the technologyThe Radiological Society of North America meeting should be another superb event for vendors and prospective purchasers of PACS technology. With what appears to be another mediocre year for big-iron

PACS vendors shouldn't oversell the technology

The Radiological Society of North America meeting should be another superb event for vendors and prospective purchasers of PACS technology. With what appears to be another mediocre year for big-iron modality introductions, PACS is expected to garner the most attention on the exhibit floor for a third straight year.

Despite all that's going well for the PACS industry, however, there remains a tendency among some vendors to exaggerate the capabilities of their products. This mindset is an unfortunate carryover from the early days of PACS, when technology claims often far exceeded their capabilities. The over-hyping of digital image management left behind a wake of disillusioned early adopters, setting back wide-scale PACS adoption by several years.

Since then, however, PACS equipment has evolved at an exponential rate. Numerous successful implementations of large-scale PACS exist and there is widespread market acceptance of the benefits of digital image management. Problem areas do remain, though, particularly in the overplaying of abilities to integrate PACS with HIS/RIS networks, as well as conformance to DICOM and HL-7 standards. It can also be difficult to ascertain how many clients PACS vendors have, with several firms distorting the number of their "sites."

With PACS equipment still at a very low level of market penetration, nothing damages the technology's credibility more than another customer who's had to return a big-ticket purchase because it didn't perform as advertised. PACS companies must avoid overselling their capabilities to their customers. It will only hurt the industry in the long run.

-Erik L. Ridley, Editor

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.